此外,胃食管交界癌 PD-L1 染色有两种不同的模式:肿瘤细胞的类晶格结构染色(lattice-like staining of tumor cells)或肿瘤结节周围的界面染色(interface staining at the periphery of tumor nodule)这两种模式都很重要,需要识别并纳入 CPS 评分。 三、阈...
[3].Oh SA, Wu DC, Cheung J, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1(7):681-691. doi:10.1038/s43018-020-0075-x [4].Juneja VR, ...
HIF1α通过直接与髓源性抑制细胞(myeloid-derived suppressor cells，MDSCs)的PD-L1近端启动子结合增加PD-L1的表达[15]，低氧条件下HIF2α可以调节透明细胞肾癌PD-L1的表达[16]。核因子-κB(nuclear factor-κB，NF-κB)也与PD-L1的表达相关。PD-L1基因启动子区存在NF-κB结合位点，Maeda等[17]报道了三阴性...
19. Shin J, Chung J-H, Kim SH, et al. Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat. 2019;51(3):1086-1097. 20. Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based asse...
Zhu Q, Cai MY, Chen CL, Hu H, Lin HX, Li M, Weng DS, Zhao JJ, Guo L and Xia JC. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. ONCOIMMUNOLOGY. 2017; 6(5):e1312240....
因此根据FDA批准的PD-L1 IHC诊断使用说明,以及诊断试剂官方给出的信息,对每个特异性抗PD-L1 IHC检测诊断针对的免疫抑制剂和对应适应症做了如下统计: 注: IC:tumor-infiltrating immune cells,肿瘤浸润性免疫细胞 TC:tumor cells,肿瘤细胞 ICP:Immune Cells Present,在肿瘤细胞区域的免疫细胞 ...
IMpower110研究结果显示,与铂类药物化疗比较,接受阿替利珠单抗治疗的PD-L1高表达[肿瘤细胞(tumor cells, TC)≥50%或免疫细胞(immune cells, IC)≥10%]患者的OS得到改善,基于这一结果,FDA批准阿替利珠单抗单药一线治疗PD-L1高表达(TC≥50%或IC≥10%)的EGFR和(或)ALK阴性的转移性NSCLC患者。
[4].Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895-904. doi:10.1084/jem.20160801 [5].Yoon HH, Jin Z, Kour O, et al. Association of PD-L1...
然而,意大利国家肿瘤研究所的研究人员在Journal for Immunotherapy of Cancer期刊上发表了一项重要研究成果“In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies”,这一发现让人大跌眼镜:PD-1抑制剂竟然会促进结直肠癌(CRC)细胞的生长,并帮助它们...
Checkmate-648研究结果显示,PD-L1肿瘤细胞阳性评分(tumor positive score, TPS)≥1%的晚期鳞癌患者中,纳武利尤单抗联合化疗组较纳武利尤单抗联合伊匹木单抗组、单纯化疗组更能获益。基于这一结果,EMA批准纳武利尤单抗联合化疗或伊匹木单抗作为PD-L1(28-8) TPS≥1%、不可切除的晚期、复发性或转移性鳞癌的一线治疗。但...